Autosomal Recessive Limb-Girdle Muscular Dystrophy Caused by BVES (POPDC1) Mutation

Autosomal Recessive Limb-Girdle Muscular Dystrophy Caused by BVES (POPDC1) Mutation is a rare, inherited muscle disease. “Autosomal recessive” means a person gets a faulty copy of the BVES (also called POPDC1) gene from both parents. The BVES gene helps heart and skeletal muscles manage signals carried by cAMP, a messenger molecule. When BVES does not work, the hip and shoulder muscles gradually weaken (the “limb-girdle” muscles). Many people also develop slow heart rhythm (bradycardia), AV-block, or other rhythm problems, so regular heart checks are essential. Some research models suggest future gene therapy could help, but this is not yet available for people. PMC+3BioMed Central+3PMC+3

This is a rare, inherited muscle disease. It mostly weakens the muscles around the hips and shoulders (the “limb-girdle” muscles). The main reason is a fault (mutation) in a gene called BVES, also known as POPDC1. This gene makes a protein that lives in the membrane of heart and skeletal muscle cells and helps those cells respond to the cell messenger cAMP and work with certain ion channels. When the BVES/POPDC1 protein does not work correctly, muscle cells become weak over time, and some people also develop heart rhythm problems (such as slow heart block or fainting). The weakness usually appears in adolescence or adulthood and progresses slowly. Blood tests often show raised creatine kinase (CK). Muscle biopsy can show typical dystrophic changes. Genetic testing confirms the diagnosis. UniProt+3MDPI+3PMC+3

Autosomal-recessive limb-girdle muscular dystrophy caused by BVES (also called POPDC1) mutations is a very rare muscle disease. It weakens the muscles around the shoulders and hips. “Autosomal recessive” means a person is affected when they inherit one faulty copy of the BVES/POPDC1 gene from each parent. The BVES/POPDC1 protein helps muscle cells and heart cells work normally by binding the messenger molecule cAMP and by keeping the cell membrane and junctions stable. When this protein does not work, skeletal muscles can become weak and damaged, and some patients also develop heart-rhythm problems like slow heartbeat or conduction block. Doctors sometimes call this condition LGMDR25. There is no cure yet, but careful rehab, heart monitoring, and supportive care can help people stay active and safe. PMC+3PMC+3PubMed+3

What causes it at the cell level (in short): POPDC1/BVES sits in the muscle cell membrane, binds cAMP, partners with other proteins in caveolae (tiny membrane pits), and helps control ion channels and cell-to-cell junctions. Disease mutations lower cAMP binding, mis-localize the protein, and disturb channels such as TREK-1, which may explain both muscle weakness and rhythm problems. PMC+2PMC+2

---

Other names

• LGMD2X (older name in the “2” series for autosomal recessive types) zfin.org

• LGMDR25 (newer “R” classification for autosomal recessive limb-girdle muscular dystrophies) MDPI+1

• POPDC1-related limb-girdle muscular dystrophy (gene-based name) PMC

• BVES-related limb-girdle muscular dystrophy (gene’s alternative symbol) PMC

---

Types

Because this condition is rare, doctors usually group people by pattern and severity rather than strict “subtypes.” You may see these patterns:

1. Skeletal-muscle–predominant: Slowly progressive weakness of hips and thighs (sometimes shoulders), often with raised CK; little or no heart involvement. malacards.org

2. Muscle + cardiac conduction disease: Muscle weakness together with atrio-ventricular block, fainting (syncope), palpitations, or need for a pacemaker. PubMed+1

3. Adult-onset vs. adolescent-onset: Both are described; adult onset is common and often slowly progressive. malacards.org

4. By variant class (missense such as S201F, or loss-of-function): Some variants disrupt how POPDC1 binds cAMP or traffics to the membrane; this can influence severity and the chance of heart rhythm problems. PMC+1

Key biology in one line: POPDC1/BVES is a cAMP-binding membrane protein in heart and skeletal muscle that interacts with ion channels (e.g., TREK-1 and Nav1.5) and helps muscle and conduction tissue work properly. MDPI+2PubMed+2

---

Causes

Important note: The direct cause is having harmful variants in both copies of the BVES/POPDC1 gene (autosomal recessive). The items below explain the different ways this can happen or the factors that modify or worsen the condition. Only the first several are true causes; the others are recognized contributors or aggravating factors in real life. I will clearly say which are “core causes” and which are “modifiers.”

Core genetic causes

1. Biallelic BVES/POPDC1 pathogenic variants. Having harmful changes in both gene copies leads to LGMDR25/LGMD2X. MDPI+1

2. Missense variants that change protein function (e.g., S201F). These can reduce cAMP binding or disturb the protein’s interactions, weakening muscle and affecting cardiac conduction. PMC

3. Loss-of-function (LoF) variants (nonsense, frameshift, splice). These may reduce the amount of functional protein at the membrane and lead to a classic limb-girdle picture. MDPI

4. Compound heterozygosity. Two different harmful variants (one on each allele) can cause disease in an autosomal recessive pattern. (General genetics principle; reported in POPDC1 families.) PubMed

5. Defects in protein trafficking of POPDC1. Some mutations misroute the protein inside the cell so it cannot reach or stay in the membrane. BioMed Central

Genetic/biologic modifiers (do not “cause” the disease alone but can shape it)

6. Changes in cAMP signaling within muscle. Because POPDC1 is a cAMP effector, signaling shifts can amplify weakness or arrhythmia risk. MDPI

7. Interactions with ion channels (TREK-1, Nav1.5). POPDC proteins modulate these channels; altered interactions may worsen conduction problems or fatigue. PubMed+1

8. Variation in related POPDC genes (POPDC2/POPDC3). While different genes, variation here may modify phenotype in research settings. (POPDC2 variants clearly cause related arrhythmia phenotypes.) ScienceDirect

9. Mitochondrial stress in muscle. Not a primary cause, but muscle energy strain can aggravate weakness in many dystrophies (general MD concept).

10. Altered membrane repair pathways. Many LGMDs share membrane instability; any second hit in membrane repair can make symptoms worse (general LGMD concept).

Lifestyle/medical modifiers (aggravating factors; not true causes)

11. High-intensity, unaccustomed eccentric exercise can provoke myalgia or CK rise.

12. Intercurrent infections (fever, viral illness) may trigger transient weakness or CK flare.

13. Statins or myotoxic drugs may exacerbate muscle symptoms in susceptible people (always discuss with a clinician).

14. Thyroid dysfunction (hypo- or hyper-thyroid) can worsen muscle symptoms if untreated.

15. Vitamin D deficiency can add fatigue and proximal weakness.

16. Severe deconditioning (prolonged inactivity) can reduce muscle reserve.

17. Malnutrition or low protein intake can impair muscle repair.

18. Electrolyte imbalance (e.g., low potassium) may worsen cramps or fatigue.

19. Sleep deprivation will increase fatigue and weakness perception.

20. Cardiac stress without monitoring (e.g., stimulants) can unmask or worsen conduction issues in people who already have POPDC1-related conduction disease—medical supervision is essential. (Heart involvement is well-documented in POPDC1 disease.) UniProt+1

---

Common symptoms

1. Hip and thigh weakness. The first complaint is often trouble climbing stairs, standing from low seats, or rising from the floor because the thigh and hip muscles are weaker. malacards.org

2. Exercise-induced aching (myalgia). Many people feel thigh or hip pain or heaviness during or after activity. MDPI

3. Slowly progressive loss of strength. The condition usually worsens over years, not days, so people notice gradual change in activity tolerance. malacards.org

4. Shoulder-girdle weakness. Lifting heavy objects or raising arms for a long time can become hard as shoulder muscles weaken over time.

5. Fatigue and low stamina. Muscles tire earlier than expected; rest helps, but the pattern tends to repeat.

6. Gait changes. The walk may become waddling or slower because hip stabilizers are weaker.

7. Frequent tripping or falls. Hip girdle weakness makes clearing the foot or stabilizing the pelvis harder, especially on uneven ground.

8. Muscle cramps. Some people experience cramps in thighs or calves after activity.

9. Elevated CK without severe symptoms. Blood tests may show high CK even when weakness seems mild. malacards.org

10. Heart rhythm symptoms. Palpitations, dizziness, or fainting (syncope) can occur due to conduction block in some patients. PubMed+1

11. Shortness of breath on exertion. This can follow reduced fitness or, rarely, heart involvement; it needs medical evaluation.

12. Calf tightness or soreness. Calves may feel tense after walking long distances.

13. Lower-back strain. As hips weaken, people may overuse back muscles, causing soreness.

14. Difficulty running or jumping. Power movements become tougher early in the course.

15. Anxiety about fainting episodes. After a syncope event due to heart block, many people fear recurrence; cardiology care and pacing can help. UniProt

---

Diagnostic tests

Physical examination (at the clinic)

1. Focused neuromuscular exam. The clinician checks bulk, tone, and pattern of weakness. In this disease, weakness is usually proximal (hips/shoulders), symmetric, and slowly progressive—consistent with limb-girdle muscular dystrophy. MDPI

2. Functional observation (sit-to-stand, stair rise). Watching how you rise from a chair or climb a step quickly shows hip-thigh weakness and helps track change over time. (Standard LGMD practice.) Medscape

3. Gowers-type maneuver. In proximal weakness, people may use hands on thighs to push up from the floor; the clinician notes whether this is present and how severe it is. (Common across LGMDs.)

4. Cardiovascular exam and vitals. Because conduction disease can occur, clinicians check pulse regularity and blood pressure and ask about fainting—this guides ECG monitoring. PubMed+1

Manual muscle and bedside functional tests

5. Manual Muscle Testing (MMT). The examiner grades strength (0–5) for hip flexion/extension, abduction, and shoulder motions. A proximal-predominant pattern supports LGMD. (General LGMD approach.)

6. Timed Up-and-Go (TUG). This simple timed walk-and-turn test tracks mobility. Slower times reflect proximal weakness and deconditioning.

7. 10-Meter Walk and 6-Minute Walk Test. These measure walking speed and endurance. They are helpful outcome measures in many muscular dystrophies.

Laboratory and pathological tests

8. Serum creatine kinase (CK). CK is often elevated—sometimes several times normal—even when symptoms are mild. Elevated CK supports a myopathic process. malacards.org

9. Comprehensive metabolic and endocrine labs. Thyroid, vitamin D, electrolytes, and other labs look for aggravating conditions that can be corrected to improve daily function (modifiers, not causes).

10. Genetic testing (targeted panel or exome). This is the definitive test. It identifies biallelic pathogenic variants in BVES/POPDC1 and confirms the diagnosis. Family testing can clarify carrier status. search.thegencc.org

11. Variant interpretation and segregation. If an uncertain variant is found, labs and clinicians review population frequency, computational predictions, and whether the variant tracks with disease in the family to decide if it is truly pathogenic. (Standard genetics practice.)

12. Muscle biopsy with immunohistochemistry. If genetics are inconclusive, a biopsy can show dystrophic change (fiber size variation, central nuclei, necrosis/regeneration). In POPDC1 disease, research shows impaired membrane trafficking of POPDC proteins on staining. malacards.org+1

Electrodiagnostic and cardiac tests

13. Electromyography (EMG). EMG usually shows a myopathic pattern (short-duration, low-amplitude motor unit potentials) rather than nerve damage. This supports a muscular dystrophy. (General LGMD principle.)

14. Nerve conduction studies (NCS). Typically near-normal or only mildly affected in muscular dystrophies; helpful to rule out neuropathy.

15. 12-lead electrocardiogram (ECG). Looks for atrio-ventricular block, bradycardia, or other rhythm issues seen in some POPDC1 patients. PubMed+1

16. Ambulatory Holter or patch monitoring. Continuous monitoring can catch intermittent pauses, blocks, or arrhythmias causing palpitations or unexplained fainting. UniProt

17. Electrophysiology (EP) study (selected cases). If symptoms and noninvasive tests suggest high-grade block or dangerous rhythms, EP testing helps decide on a pacemaker or other therapy. (Cardiology practice consistent with POPDC1 reports.) UniProt

Imaging and advanced assessments

18. Cardiac imaging (echocardiogram ± cardiac MRI). These look at structure and function, help exclude other causes, and provide a baseline because POPDC1 disease may include cardiac involvement. UniProt

19. Muscle MRI (thighs and pelvis). Muscle MRI maps which muscles are most affected and how much fat replacement is present. Patterns can support LGMD and help with follow-up. (General LGMD tool.)

20. DEXA or body composition scan (optional). This can quantify lean muscle mass changes over time to track disease progression and response to therapy.

Non-pharmacological treatments

1. Individualized physiotherapy program
   Purpose: Maintain strength you still have, protect joints, and delay contractures.
   Mechanism: Low-to-moderate resistance and aerobic activities improve muscle endurance without overwork; stretching maintains tendon length and joint range. Programs are tailored to fatigue levels. PMC+1

2. Submaximal aerobic training (walking, cycling, swimming)
   Purpose: Improve stamina, breathing efficiency, and daily function.
   Mechanism: Repeated, low-impact aerobic work boosts mitochondrial efficiency and cardiovascular fitness with low muscle damage risk in muscular dystrophies. Frontiers

3. Gentle progressive resistance training
   Purpose: Strengthen proximal muscles enough to aid transfers and posture.
   Mechanism: Carefully dosed sets two to three times per week can increase knee flexion strength and function without accelerating degeneration when supervised. Frontiers

4. Daily stretching and positioning
   Purpose: Prevent contractures of hips, knees, and shoulders.
   Mechanism: Sustained stretches and night splints keep muscle–tendon units lengthened; consistency matters more than intensity. Muscular Dystrophy Association

5. Occupational therapy (OT)
   Purpose: Conserve energy and maintain independence at home/school/work.
   Mechanism: Task simplification, ergonomic tools, and pacing strategies reduce fatigue burden and joint strain, preserving function longer. PubMed

6. Orthoses and mobility aids (AFOs, canes, wheelchairs)
   Purpose: Improve safety and walking efficiency; reduce falls.
   Mechanism: Braces stabilize weak joints; mobility devices optimize gait mechanics and reduce compensatory overuse. Physiopedia

7. Cardiac surveillance and device therapy planning
   Purpose: Detect and treat rhythm problems early.
   Mechanism: Regular ECG/Holter and echo; timely implantation of pacemaker/ICD when indicated lowers syncope and sudden-death risk in neuromuscular disorders. heartrhythmjournal.com+1

8. Respiratory assessment and support
   Purpose: Catch nocturnal hypoventilation and weak cough early.
   Mechanism: Spirometry, sleep studies, and cough-assist/NIV when needed maintain oxygenation and reduce infections. (Approach extrapolated from broader muscular dystrophy care.) PMC

9. Falls-prevention program
   Purpose: Reduce fractures and head injuries.
   Mechanism: Home hazard checks, balance practice, proper footwear, and assistive tech cut fall risk in proximal weakness. PubMed

10. Nutrition counseling
    Purpose: Support muscle metabolism and healthy weight.
    Mechanism: Adequate protein, vitamin D, calcium, and omega-3 intake; avoid weight gain that worsens mobility or heart strain. MDPI

11. Fatigue management and energy conservation
    Purpose: Do more with less fatigue.
    Mechanism: Pacing, activity diaries, and rest scheduling lower overwork weakness and help sustain participation. PubMed

12. Pain management without over-sedation
    Purpose: Control musculoskeletal pain.
    Mechanism: Heat/ice, gentle manual therapy, TENS, and graded activity; cautious use of medicines given respiratory and cardiac comorbidities. PubMed

13. Speech and swallowing screening
    Purpose: Identify rare bulbar involvement early.
    Mechanism: SLP evaluates dysphagia or dysarthria; strategies lower aspiration risk. (General neuromuscular best practice.) PMC

14. Mental-health support
    Purpose: Address anxiety/depression and caregiver stress.
    Mechanism: Counseling and peer groups improve coping and adherence to rehab. PubMed

15. School/work accommodations
    Purpose: Maintain roles and income.
    Mechanism: Flexible schedules, remote options, adaptive equipment, and rest breaks reduce disability impact. PubMed

16. Genetic counseling for the family
    Purpose: Explain autosomal-recessive inheritance and carrier risks.
    Mechanism: Counselors discuss testing, reproductive options, and cascade screening. PMC

17. Vaccinations (influenza, pneumococcal, COVID-19 as applicable)
    Purpose: Prevent respiratory infections that can worsen weakness.
    Mechanism: Immunization lowers infection-related hospitalizations in neuromuscular disease. PMC

18. Sleep-disordered breathing management
    Purpose: Improve daytime energy and heart rhythm stability.
    Mechanism: Sleep study and CPAP/BiPAP when indicated stabilize oxygen and CO₂. PMC

19. Avoidance of myotoxic overexertion
    Purpose: Train smart, not hard.
    Mechanism: Replace eccentric-heavy or max-effort training with controlled, submaximal work to reduce muscle damage. Frontiers

20. Clinical-trial awareness
    Purpose: Understand research options.
    Mechanism: New vectors and gene strategies are being studied for BVES/POPDC1; animal work with AAV9-BVES shows promise but is not yet approved in humans. ScienceDirect+1

---

Drug treatments

There are no FDA-approved drugs specifically for LGMDR25. Medicines are used to treat heart-rhythm problems, heart failure, pain, and related issues. Doses must be individualized by a cardiologist/neuromuscular specialist. FDA label citations below confirm indications, dosing ranges, and safety for each drug’s approved use—not for LGMDR25 itself.

1. Metoprolol succinate (extended-release, β1-blocker)
   Class: Beta-blocker. Typical dose: 25–200 mg once daily, titrated. Timing: Daily. Purpose: Control sinus tachycardia, rate-control in atrial arrhythmias, and treat HFrEF if present. Mechanism: Blocks β1-adrenergic receptors to slow heart rate, reduce myocardial oxygen demand, and improve HF outcomes. Side effects: Fatigue, bradycardia, hypotension; caution with conduction disease. FDA Access Data

2. Amiodarone
   Class: Class III antiarrhythmic. Typical dose: Loading 800–1600 mg/day, then 400 mg/day maintenance (individualize). Timing: Daily; long half-life. Purpose: Control complex atrial/ventricular arrhythmias when other drugs fail. Mechanism: Prolongs repolarization and slows conduction in multiple channels. Side effects: Thyroid, pulmonary, hepatic toxicity; photosensitivity—requires monitoring. FDA Access Data

3. Propafenone
   Class: Class IC antiarrhythmic. Dose: Individualized per label. Purpose: Selected supraventricular arrhythmias in structurally suitable hearts. Mechanism: Sodium-channel blockade; some β-blocking. Side effects: Proarrhythmia; avoid with significant structural heart disease. FDA Access Data

4. Flecainide
   Class: Class IC antiarrhythmic. Dose/timing: Per label; careful titration. Purpose: Paroxysmal atrial arrhythmias in appropriate candidates. Mechanism: Sodium-channel block; slows conduction. Side effects: Proarrhythmia; use with specialist oversight. FDA Access Data

5. Mexiletine
   Class: Class IB antiarrhythmic. Dose: Per label; divided oral doses. Purpose: Ventricular arrhythmias; in some NMDs, may help painful myotonia (off-label). Mechanism: Sodium-channel blockade in depolarized tissue. Side effects: GI upset, tremor; ECG monitoring. FDA Access Data

6. Ivabradine
   Class: If (funny-current) inhibitor. Dose: 5–7.5 mg twice daily (adults; per label). Purpose: Reduce heart rate in HFrEF with sinus rhythm when β-blockers are not enough or not tolerated. Mechanism: Slows SA-node pacemaker current without lowering blood pressure much. Side effects: Bradycardia, luminous phenomena. FDA Access Data

7. Lisinopril
   Class: ACE inhibitor. Dose: 5–40 mg daily, titrated. Purpose: Treat hypertension and HFrEF if present; afterload reduction can protect remodeling. Mechanism: Blocks angiotensin-converting enzyme; vasodilation; neurohormonal modulation. Side effects: Cough, hyperkalemia, angioedema; fetal toxicity—avoid in pregnancy. FDA Access Data

8. Spironolactone
   Class: Mineralocorticoid receptor antagonist. Dose: Often 12.5–50 mg daily in HF (per label). Purpose: HFrEF add-on to improve survival and control edema. Mechanism: Blocks aldosterone’s fibrotic and sodium-retaining effects. Side effects: Hyperkalemia, renal issues, gynecomastia. FDA Access Data

9. Apixaban
   Class: Direct factor Xa inhibitor. Dose: 5 mg twice daily (or 2.5 mg in selected patients). Purpose: Stroke prevention in non-valvular atrial fibrillation when AF occurs. Mechanism: Inhibits Xa to reduce thrombin generation and clot formation. Side effects: Bleeding; renal dose adjustment rules apply. FDA Access Data

10. Loop diuretics (e.g., furosemide)
    Class: Diuretic. Dose: Individualized. Purpose: Treat volume overload in HF or edema from reduced mobility. Mechanism: Blocks Na-K-2Cl in loop of Henle to increase diuresis. Side effects: Electrolyte loss, hypotension; monitor labs. (Representative FDA labels document indications and cautions.) FDA Access Data

11. ACE/ARB alternatives (e.g., lisinopril as above; ARB if ACE-intolerant)
    Purpose/Mechanism: Neurohormonal blockade for HF or hypertension in affected individuals. Note: Choose based on tolerance and comorbidities; follow labeling. FDA Access Data

12. β-blocker alternatives (bisoprolol, carvedilol)
    Purpose: HF benefit and arrhythmia rate control. Mechanism: β-blockade; carvedilol adds α-blockade. Side effects: Bradycardia, hypotension. (Use FDA labeling for each agent.) FDA Access Data

13. SGLT2 inhibitors for HFrEF (e.g., dapagliflozin)
    Purpose: Reduce HF hospitalization and CV death in HFrEF regardless of diabetes status (when HF present). Mechanism: Natriuresis, improved cardiac metabolism. Side effects: GU infections, volume depletion. (Use official FDA labels for chosen agent.) FDA Access Data

14. Calcium-channel blockers (selected cases)
    Purpose: Symptom control in certain supraventricular tachyarrhythmias if appropriate. Mechanism: AV-node slowing (non-DHP). Caution: Avoid in reduced EF; specialist supervision. (Label-based cautions.) PMC

15. Electrolyte optimization (potassium, magnesium as medicines)
    Purpose: Reduce arrhythmia risk. Mechanism: Corrects pro-arrhythmic hypokalemia/hypomagnesemia; often paired with diuretics/antiarrhythmics per label monitoring recommendations. FDA Access Data

16. Pain medicines with neuromuscular caution
    Purpose: Treat musculoskeletal pain without respiratory depression. Mechanism: Prefer acetaminophen; use NSAIDs carefully for GI/renal risk in low-mobility states. (Label-based safety principles.) PMC

17. Vaccines (medicinal biologics)
    Purpose: Prevent respiratory infections that worsen function. Mechanism: Induce protective immunity. Use: As per national schedules and labels; discuss with clinician. PMC

18. Antibiotics when aspiration or pneumonia occurs
    Purpose: Treat infections promptly. Mechanism: Pathogen-directed therapy reduces hospital days and decline. (Use FDA labeling for selected antibiotic.) PMC

19. Anticoagulation alternatives (e.g., warfarin) when DOACs unsuitable
    Purpose: Stroke prevention in AF with special conditions (e.g., mechanical valves—though uncommon here). Mechanism: Vitamin K antagonism. Side effects: Bleeding; INR monitoring. FDA Access Data

20. Specialist-guided antiarrhythmic strategy overall
    Purpose: Choose safest agent for the individual heart substrate in neuromuscular disease. Mechanism: Follow consensus pathways for pacing/ICD thresholds and drug selection. Note: Invasive options considered when medicines fail. heartrhythmjournal.com

---

Dietary molecular supplements

1. Creatine monohydrate
   Dose: Commonly 3–5 g/day after a short loading phase if used. Function: Energy buffer for fast ATP recycling in muscle. Mechanism: Increases phosphocreatine stores, improving strength/endurance in several muscular dystrophies in short-term trials. PMC+1

2. Coenzyme Q10 (ubiquinone)
   Dose: Often 100–300 mg/day. Function: Electron transport and antioxidant. Mechanism: Supports mitochondrial function; small studies suggest fatigue benefits in muscular diseases; evidence remains limited. MDPI

3. Vitamin D3
   Dose: Per 25-OH D level; often 800–2000 IU/day if deficient. Function: Bone health, muscle function. Mechanism: Repletion helps bone/mineral metabolism; performance effects are inconsistent in trials—use to correct deficiency. Taylor & Francis Online+1

4. Omega-3 fatty acids (EPA/DHA)
   Dose: ~1–2 g/day combined EPA+DHA (food or capsules). Function: Anti-inflammatory membrane lipids. Mechanism: May dampen muscle inflammation and support cardiac health. Evidence in muscular dystrophy is emerging. MDPI

5. L-carnitine
   Dose: 1–2 g/day (divided). Function: Fatty-acid transport into mitochondria. Mechanism: May aid energy metabolism; supportive evidence is modest; watch for GI side effects. MDPI

6. Taurine
   Dose: 1–3 g/day (divided). Function: Membrane stabilization and calcium handling. Mechanism: Antioxidant/osmolyte actions may protect myofibers; human data limited. MDPI

7. Curcumin
   Dose: 500–1000 mg/day of enhanced-bioavailability forms. Function: Anti-inflammatory polyphenol. Mechanism: NF-κB modulation could reduce muscle damage signaling; evidence mainly preclinical or small human studies. MDPI

8. Resveratrol
   Dose: 150–300 mg/day. Function: Antioxidant; SIRT1 activation. Mechanism: May enhance mitochondrial biogenesis; human efficacy uncertain. MDPI

9. Alpha-lipoic acid
   Dose: 300–600 mg/day. Function: Redox cofactor and antioxidant. Mechanism: Recycles glutathione/vitamins C and E; potential to reduce oxidative stress in muscle. MDPI

10. Zinc + Selenium (trace minerals)
    Dose: Zinc 8–11 mg/day; selenium ~55 µg/day (diet then supplement only if low). Function: Antioxidant enzyme cofactors. Mechanism: Support redox enzymes (e.g., GPx, SOD); replete only if deficient to avoid toxicity. MDPI

---

Drugs in the immunity-booster / regenerative / stem-cell

Important: There are no FDA-approved regenerative or stem-cell drugs for LGMDR25. The items below reflect research concepts or related therapies; use only in clinical trials or approved indications.

1. AAV9-BVES gene therapy (experimental)
   What it is: A lab-made virus carrying a healthy BVES gene. Dose: Trial-dependent. Function/mechanism: Delivers BVES to muscles; in mice, improved pathology. Status: Preclinical/early research; not FDA-approved. ScienceDirect

2. Exon-agnostic AAV delivery platforms (program-level)
   What it is: Vector systems adapted from LGMD trials. Function: Restore missing protein activity. Note: Several LGMD AAV trials were placed on clinical hold in 2025 for safety review—underscores need for caution. U.S. Food and Drug Administration

3. Cell-based myogenic progenitor approaches (investigational)
   What it is: Transplanting or stimulating muscle progenitors. Function: Replace or repair damaged fibers. Mechanism: Engraftment and fiber fusion; still experimental in LGMD. PubMed

4. CRISPR/Cas editing strategies (preclinical)
   What it is: Gene editing to correct POPDC1 mutations. Function: Fixes the underlying DNA in target cells. Status: Conceptual/preclinical for this subtype; clinical use would require rigorous trials. PMC

5. IVIG (context-specific, not disease-modifying for LGMDR25)
   What it is: Immune globulin. Function: Modulates immune response; used in autoimmune myopathies. Note: Not indicated for BVES-LGMD unless there’s a separate immune process. PMC

6. Cardiac conduction devices (not a drug but regenerative-adjacent)
   What it is: Pacemaker/ICD implantation when indicated. Function: Restores safe rhythm and prevents sudden death; complements any future gene therapy. heartrhythmjournal.com

---

Surgeries / procedures

1. Pacemaker implantation
   Why: Treat symptomatic bradycardia or AV-block due to conduction disease. Procedure: Leads placed in heart chambers; generator under skin; restores reliable pacing. heartrhythmjournal.com

2. Implantable cardioverter-defibrillator (ICD)
   Why: Prevent sudden death in high-risk arrhythmias. Procedure: Device detects dangerous rhythms and shocks or overdrives them. PMC

3. Catheter ablation (selected arrhythmias)
   Why: Eliminate a focal tachycardia when drugs fail or are poorly tolerated. Procedure: Catheters map and ablate abnormal tissue. heartrhythmjournal.com

4. Contracture release / tendon lengthening (selected cases)
   Why: Improve severe joint stiffness that limits care or mobility. Procedure: Orthopedic surgery to lengthen tendon and improve range. PubMed

5. Spinal deformity surgery (if scoliosis becomes severe)
   Why: Improve seating, care, and respiratory mechanics. Procedure: Stabilization and correction with instrumentation. PubMed

---

Preventions

1. Regular cardiology follow-up with ECG/Holter. Detect silent conduction disease early. heartrhythmjournal.com

2. Structured, submaximal exercise—not all-out training. Avoid overwork weakness. Frontiers

3. Daily stretching to prevent contractures. Protects mobility. Muscular Dystrophy Association

4. Vaccinations as advised. Lower respiratory infection risk. PMC

5. Nutrition with adequate protein and vitamin D. Support muscle and bone. MDPI

6. Fall-proof home and use aids early. Reduce injuries. PubMed

7. Medication review to avoid pro-arrhythmic or sedating combinations. Keep electrolytes normal. FDA Access Data

8. Sleep evaluation if snoring or morning headaches appear. Treat nocturnal hypoventilation early. PMC

9. Plan pregnancy with a genetics team. Understand autosomal-recessive risks. PMC

10. Know emergency signs (syncope, chest pain, palpitations). Seek urgent care. heartrhythmjournal.com

---

When to see doctors (red-flag checklist)

See a neuromuscular specialist and a cardiologist promptly if you notice new falls, worsening trouble rising from chairs, rapid fatigue, palpitations, dizziness or fainting, chest pain, very slow or very fast pulse, shortness of breath at rest or at night, leg swelling, or sudden weakness after an illness or new medicine. Heart-rhythm issues are common in POPDC1 disease and can be silent—regular monitoring is essential even if you feel “okay.” PMC+1

---

What to eat” and “what to avoid”

Eat more:
• Lean proteins (fish, poultry, beans, dairy) to meet daily protein needs for muscle upkeep.
• Omega-3-rich foods (fatty fish, flax, walnuts) for anti-inflammatory support.
• Produce of many colors for antioxidants and fiber.
• Calcium- and vitamin-D sources for bone health.
• Adequate fluids and electrolytes, especially during heat or illness. MDPI+1

Avoid/limit:
• Ultra-processed foods with excess salt and sugar (can worsen blood pressure and weight).
• Excess alcohol (worsens muscle and heart function).
• Unregulated “muscle boosters” making cure claims.
• Very high-intensity eccentric training plans paired with low recovery.
• High-salt diets if you have cardiomyopathy or edema. MDPI+1

---

Frequently asked questions

1. Is LGMDR25 the same as “BVES muscular dystrophy”?
   Yes—BVES is the same gene as POPDC1; both names describe the same condition. NCBI

2. How is it inherited?
   Autosomal recessive—both parents usually carry one faulty copy; the child needs two to be affected. PMC

3. What are the first symptoms?
   Often hip/shoulder weakness, trouble climbing stairs, and easy fatigue; some patients also have early rhythm problems. PubMed

4. Does everyone get heart problems?
   Not everyone, but many patients with POPDC1 variants develop conduction disease or arrhythmias, so routine screening is key. PMC

5. Is there a cure?
   No approved cure yet. Gene therapy is being studied in animals and early pipelines. ScienceDirect

6. Are AAV gene therapies available for LGMDR25 now?
   No. Recent FDA safety actions in other LGMD programs show why careful trials are needed first. U.S. Food and Drug Administration

7. What exercise is safest?
   Low-impact aerobic and supervised, moderate resistance training; avoid all-out or eccentric-heavy programs. Frontiers

8. Can creatine help?
   Short- to medium-term trials in muscular dystrophies show modest strength gains; discuss dosing and kidney health with your clinician. PMC

9. Do vitamins cure the disease?
   No. Use nutrition to correct deficiencies (e.g., vitamin D) and support general health; avoid megadoses without medical guidance. American Journal of Clinical Nutrition

10. Why so much focus on the heart?
    POPDC1 is expressed in heart and skeletal muscle; rhythm issues can be serious but are manageable if detected early. PMC

11. When might I need a pacemaker or ICD?
    If you develop symptomatic bradycardia, AV block, or high-risk ventricular arrhythmias—decisions follow neuromuscular arrhythmia consensus guidance. heartrhythmjournal.com

12. Can children be tested?
    Yes—genetic testing confirms diagnosis, guides family planning, and informs monitoring plans. PMC

13. Are steroids used?
    Unlike Duchenne, routine long-term steroids are not standard for LGMDR25; therapy focuses on rehab and cardiac care. PubMed

14. What about school and work?
    Occupational therapy and accommodations (pacing, adaptive tools, remote options) help maintain roles and independence. PubMed

15. Where is the field going?
    Mechanistic work on POPDC1–cAMP signaling and ion channels (like TREK-1) is opening new targets for therapy and precision monitoring. Cell

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 11, 2025.